Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Marinus Pharmaceuticals, Inc is a biotechnology business based in the US. Marinus Pharmaceuticals shares (MRNS) are listed on the NASDAQ and all prices are listed in US Dollars. Marinus Pharmaceuticals employs 65 staff and has a trailing 12-month revenue of around USD$171,000.
|52-week range||USD$4.16 - USD$17.14|
|50-day moving average||USD$13.9347|
|200-day moving average||USD$12.7978|
|Wall St. target price||USD$28.44|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.982|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-55.57%|
|Return on equity TTM||-107.68%|
|Market capitalisation||USD$575.2 million|
TTM: trailing 12 months
There are currently 4.2 million Marinus Pharmaceuticals shares held short by investors – that's known as Marinus Pharmaceuticals's "short interest". This figure is 2% down from 4.3 million last month.
There are a few different ways that this level of interest in shorting Marinus Pharmaceuticals shares can be evaluated.
Marinus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Marinus Pharmaceuticals shares currently shorted divided by the average quantity of Marinus Pharmaceuticals shares traded daily (recently around 334098.08306709). Marinus Pharmaceuticals's SIR currently stands at 12.52. In other words for every 100,000 Marinus Pharmaceuticals shares traded daily on the market, roughly 12520 shares are currently held short.
However Marinus Pharmaceuticals's short interest can also be evaluated against the total number of Marinus Pharmaceuticals shares, or, against the total number of tradable Marinus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Marinus Pharmaceuticals's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Marinus Pharmaceuticals shares in existence, roughly 120 shares are currently held short) or 0.1177% of the tradable shares (for every 100,000 tradable Marinus Pharmaceuticals shares, roughly 118 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Marinus Pharmaceuticals.
Find out more about how you can short Marinus Pharmaceuticals stock.
We're not expecting Marinus Pharmaceuticals to pay a dividend over the next 12 months.
Marinus Pharmaceuticals's shares were split on a 1:4 basis on 23 September 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Marinus Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Marinus Pharmaceuticals shares which in turn could have impacted Marinus Pharmaceuticals's share price.
Over the last 12 months, Marinus Pharmaceuticals's shares have ranged in value from as little as $4.16 up to $17.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Marinus Pharmaceuticals's is 1.5662. This would suggest that Marinus Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors and exhibits anti seizure, antidepressant, and anxiolytic actions through its effects on. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment resistant depression. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.